Fresenius Medical Care Reports Excellent Fourth Quarter and Full Year 2007 Results and Provides Strong Outlook for 2008

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) (FWB: FME): Summary Fourth Quarter 2007:     Net revenue $ 2,569 million + 9% Operating income (EBIT) $ 428 million + 21% Net income $ 197 million + 30% Earnings per share $ 0.67 + 29% Summary Full Year 2007:     Net revenue $ 9,720 million + 14% Operating income (EBIT) $ 1,580 million + 20% Net income $ 717 million + 34% Earnings per share $ 2.43 + 33%   Dividend Proposal Ordinary Share € 0.54 + 15% Preference Share € 0.56 + 14% Fresenius Medical Care AG & Co. KGaA ("the Company”), the world’s largest provider of Dialysis Products and Services, today announced its results for the fourth quarter and full year of 2007. Fourth Quarter 2007: Revenue Net revenue for the fourth quarter 2007 increased by 9% to $2,569 million (6% at constant currency) compared to the fourth quarter 2006. Organic revenue growth worldwide was 4%. Dialysis Services revenue grew by 6% to $1,856 million (4% at constant currency) in the fourth quarter of 2007. Dialysis Product revenue increased by 18% to $713 million (10% at constant currency) in the same period. North America revenue increased by 3% to $1,706 million. Dialysis Services revenue grew by 1% to $1,526 million. Excluding effects of the divestiture of the perfusion business, Dialysis Service revenue increased by 3%. Average revenue per treatment for the U.S. clinics decreased by 1% to $325 in the fourth quarter 2007 compared to $328 for the same quarter in 2006. At the same time, due to extremely good cost containment, the comparable costs per treatment decreased by 2% to $266 per treatment also contributing to a further margin expansion of 70 basis points in North America. Dialysis Product revenue increased by 17% to $180 million again well above market led by strong sales of our 2008K hemodialysis machines, peritoneal dialysis products and the phosphate binding drug PhosLo. International revenue was $863 million, an increase of 24% (12% at constant currency) compared to the fourth quarter of 2006. Organic revenue growth of the international segment was 7%. Dialysis Services revenue reached $331 million, an increase of 35% (22% at constant currency). Dialysis Product revenue rose by 18% to $533 million (7% at constant currency), led by strong peritoneal dialysis products and dialyzers. Earnings Operating income (EBIT) increased by 21% to $428 million compared to $354 million in the fourth quarter 2006. Operating income for the fourth quarter 2006 includes costs of $25 million related to restructuring costs and in-process R&D. Excluding these effects, operating income for the fourth quarter 2007 increased by 13%. The operating margin improved from 16.1% in the fourth quarter 2006 excluding the one-time costs to 16.6% in 2007. Operating income (EBIT) before one-time items Three months ended December 31, (in US-$ million)   2007     2006   % Change Operating income (EBIT)   428     354   + 21% Cost of restructuring and in-process R&D   -     25     Operating income (EBIT) before one-time items   428     379   + 13% In North America, the operating margin increased from 17.1% (excluding the effects of one-time items) by 70 basis points to 17.8% due to the new PhosLo business, higher product sales and decreased operating costs per treatment. In the International segment, the operating margin also increased by 70 basis points to 18.4% mainly due to higher growth in the emerging markets and increased efficiencies. Net interest expense for the fourth quarter 2007 was $90 million compared to $96 million in the same quarter of 2006. This positive development was mainly attributable to lower average interest rates and a lower debt level. Income tax expense was $135 million for the fourth quarter of 2007 compared to $99 million in the fourth quarter of 2006, reflecting effective tax rates of 39.8% and 38.5%, respectively. Net income for the fourth quarter 2007 was $197 million, an increase of 30%. Net income increased by 16% when compared to the fourth quarter 2006 excluding the effects of one-time items in 2006. Net income before one-time items Three months ended December 31, (in US-$ million)   2007     2006   % Change Net income   197     152   + 30% Cost of restructuring and in-process R&D   -     18     Net income before one-time items   197     170   + 16% Earnings per share (EPS) for the fourth quarter of 2007 rose by 29% to $0.67 per ordinary share compared to $0.52 for the fourth quarter of 2006. The weighted average number of shares outstanding for the fourth quarter of 2007 was approximately 296.3 million shares compared to 295.0 million shares for the fourth quarter of 2006. The increase in shares outstanding resulted from stock option exercises in 2007. Cash Flow In the fourth quarter of 2007, the Company generated $309 million in cash from operations, representing approximately 12% of revenue, clearly ahead of our target. The extremely strong cash flow generation was primarily supported by higher earnings and a stable working capital. A total of $184 million was spent for capital expenditures, net of disposals. Free Cash Flow before acquisitions was $125 million compared to $266 million in the fourth quarter of 2006 on a reported basis. A total of $118 million in cash was used for acquisitions. Full Year 2007: The operations of Renal Care Group (RCG) are included in the Company’s consolidated statements of income and cash flows from April 1, 2006, therefore, the current results for the full year 2007 are not directly comparable with the results of the full year 2006. Revenue and Earnings Net revenue for 2007 was $9,720 million, up 14% from 2006. At constant currency, net revenue rose by 12%. Organic growth was 6% in 2007. Operating income (EBIT) increased by 20% to $1,580 million compared to $1,318 million in 2006. Operating income for the full year 2006 includes cost of $37 million as a result of restructuring, the transformation of the Company’s legal form and in-process R&D, and a gain from the clinic divestitures of $40 million. Excluding these items, operating income for 2007 increased also by 20%. This performance resulted in an operating margin of 16.3% compared to 15.5% for the year 2006. Operating income (EBIT) before one-time items Twelve months ended December 31, (in US-$ million)   2007   2006   % Change Operating income (EBIT)   1,580   1,318   + 20% Cost of restructuring, transformation and in-process R&D   -   37     Gain from divestiture   -   (40)     Operating income (EBIT) before one-time items   1,580   1,315   + 20% Net interest expense for the full year 2007 was $371 million compared to $351 million in 2006. The increase was mainly the result of additional interest expense partially offset by the write-off in 2006 of deferred financing costs related to the 2003 senior credit facility of $15 million, both in conjunction with the financing of the RCG acquisition. Income tax expense was $466 million for the full year compared to $413 million in 2006, reflecting tax rates of 38.5% and 42.8%, respectively. The tax rate for 2006 was impacted by tax payments in the U.S mainly related to the gain on the divestiture of dialysis clinics in the U.S. Excluding this impact, the effective tax rate for 2006 was at 39.8%. For the full year 2007, net income was $717 million, up 34% from 2006. Net income for 2007 increased by 25% compared to 2006 excluding the effects of one-time items in 2006. Net income before one-time items Twelve months ended December 31, (in US-$ million)   2007   2006   % Change Net income   717   537   + 34% Cost of restructuring, transformation and in-process R&D   -   24     Write-off FME prepaid financing fees   -   9     Loss from divestiture   -   4     Net income before one-time items   717   574   + 25% For the full year 2007, earnings per ordinary share rose by 33% to $2.43. The weighted average number of shares outstanding during 2007 was approximately 295.7 million. Cash Flow Cash from operations during the full year 2007 was $1,200 million compared to $908 million for 2006 on a reported basis. Excluding the effects of one-time items, cash from operations was $1,106 million for 2006. The increase compared to prior year was mainly due to increased earnings. A total of $549 million was used for capital expenditures, net of disposals. Free Cash Flow before acquisitions for 2007 was $651 million compared to $458 million in 2006. The underlying Free Cash Flow before acquisitions and the effects of one-time items for 2006 was $656 million. A total of $228 million in cash was used for acquisitions, net of divestitures. Free Cash Flow after acquisitions for the full year 2007 was $423 million. Please refer to the attachments for a complete overview on the fourth quarter and the full year of 2007 and the reconciliation of non-GAAP financial measures included in this release to the most comparable GAAP financial measures. Patients – Clinics – Treatments As of December 31, 2007, Fresenius Medical Care treated 173,863 patients worldwide, which represents a 6% increase in patients compared to last year. North America provided dialysis treatments for 121,431 patients, an increase of 3%. Including 33 clinics managed by Fresenius Medical Care North America, the number of patients in North America was 123,273. The International segment served 52,432 patients, an increase of 15% over last year. As of December 31, 2007, the Company operated a total of 2,238 clinics worldwide. This is comprised of 1,602 clinics in North America, an increase of 3%, and 636 clinics in the International segment, an increase of 16%. Fresenius Medical Care delivered approximately 26.44 million dialysis treatments worldwide during 2007. This represents an increase of 11% year over year. North America accounted for 18.45 million treatments, an increase of 9%, and the International segment delivered 7.99 million treatments, an increase of 16% over last year. Employees As of December 31, 2007, Fresenius Medical Care had 61,406 employees (full-time equivalents) worldwide compared to 56,803 employees at the end of 2006. The increase of 4,603 employees is primarily due to continued organic growth in the U.S. and acquisitions in Asia. Dividends The Company will continue to follow an earnings-driven dividend policy. For the eleventh consecutive year, shareholders can expect to receive an increased annual dividend for the fiscal year 2007. At the Annual General Meeting to be held on May 20, 2008, shareholders will be asked to approve a dividend of €0.54 per ordinary share, an increase of 15% from 2006 (€0.47) and €0.56 per preference share, an increase of 14% from 2006 (€0.49). Debt/EBITDA Ratio The ratio of debt to Earnings before Interest, Taxes and Amortization (EBITDA) decreased from 3.23 at the end of 2006 to 2.84 at the end of 2007. Rating There have been no rating changes in the fourth quarter 2007, Standard & Poor’s Ratings Services rates the Company’s corporate credit rating as 'BB' with a ‘stable’ outlook. Moody's rates the Company’s corporate credit rating as ‘Ba2’ with a ‘positive’ outlook. Refinancing of Trust Preferred Securities At the beginning of February, we refinanced our Capital Trust II and III Trust Preferred Securities. They were mandatorily redeemable after a period of ten years, expiring on February 1, 2008. The stated amount of Capital Trust II was $450 million, with a fixed interest rate of 7 7/8%; the stated amount of Capital Trust III totaled DM300 million, with an interest rate of 7 3/8%. Fresenius Medical Care’s existing financing facilities were utilized to affect the refinancing. Outlook for 2008 For the full year 2008, the Company expects to achieve revenue of more than $10.4 billion, an increase of more than 7%. Net income is expected to be between $805 million and $825 million in 2008, an increase of 12% to 15%. The Company expects to spend $650 to $750 million on capital expenditures and $150 to $250 million on acquisitions. The debt/EBITDA ratio is expected to decrease below 2.8 by the end of 2008. For 2010, Fresenius Medical Care continues to expect revenue of more than $11.5 billion. Earnings after tax are projected to grow in the low- to mid-teens per year. Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "Our excellent performance in 2007 achieving record revenue and earnings for the year reflects the strong demand for our products and services worldwide. Both, the North American segment and the International segment contributed to this outstanding performance. Overall, we continued to grow above market in our global product business and are the leading provider of dialysis services in all four major regions in the world. We are pleased to have again exceeded our guidance in 2007 and are proposing to deliver our eleventh consecutive dividend increase to our shareholders. We have made good progress on our growth initiatives and with our global presence, we are confident to continue our strong performance in 2008.” Video Webcast Fresenius Medical Care will hold an analyst meeting at its headquarters in Bad Homburg, Germany, to discuss the results of the fourth quarter and the full year of 2007 on Wednesday, February 20, 2008, at 3.15pm CET / 9.15am EST. The Company invites investors to view the live webcast of the meeting at the Company’s website www.fmc-ag.com in the "Investor Relations” section. A replay will be available shortly after the meeting. Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,600,000 individuals worldwide. Through its network of 2,238 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 173,863 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P). For more information about Fresenius Medical Care visit the Company’s website at www.fmc-ag.com. This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. Fresenius Medical CareStatements of Earnings   Three Months EndedDecember 31,       Twelve Months EndedDecember 31,     (in US-$ thousands, except share and per share data)   2007   2006   % Change   2007   2006   % Change   Net revenue Dialysis Care 1,856,331 1,749,326 6.1 % 7,213,000 6,377,390 13.1 % Dialysis Products 712,957 603,025 18.2 % 2,507,314 2,121,648 18.2 % Total net revenue 2,569,288 2,352,351 9.2 % 9,720,314 8,499,038 14.4 %   Cost of revenue 1,673,172 1,532,894 9.2 % 6,364,519 5,621,482 13.2 % Gross profit 896,116 819,457 9.4 % 3,355,795 2,877,556 16.6 % Selling, general and administrative 445,469 451,808 -1.4 % 1,709,150 1,548,369 10.4 % Gain on sale of dialysis clinics - - - (40,233 ) Research and development 22,977 13,946 64.8 % 66,523 51,293 29.7 % Operating income (EBIT) 427,670 353,703 20.9 % 1,580,122 1,318,127 19.9 %   Interest income (9,540 ) (5,588 ) 70.7 % (28,588 ) (20,432 ) 39.9 % Interest expense 99,268 101,764 -2.5 % 399,635 371,678 7.5 % Interest expense, net 89,728 96,176 -6.7 % 371,047 351,246 5.6 % Earnings before income taxes and minority interest   337,942 257,527 31.2 % 1,209,075 966,881 25.0 % Income tax expense 134,555 99,088 35.8 % 465,652 413,489 12.6 % Minority interest 5,973 6,415 26,293 16,646 Net income 197,414 152,024 29.9 % 717,130 536,746 33.6 %   Operating income (EBIT) 427,670 353,703 20.9 % 1,580,122 1,318,127 19.9 % Depreciation and amortization 103,468 87,440 18.3 % 363,329 308,698 17.7 % EBITDA 531,138 441,143 20.4 % 1,943,451 1,626,825 19.5 %   Total bad debt expenses 49,235 48,456 201,998 177,285   Earnings per ordinary share $0.67 $0.52 29.3 % $2.43 $1.82 32.9 % Earnings per ordinary ADS $0.67 $0.52 29.3 % $2.43 $1.82 32.9 %   Weighted average number of shares   Ordinary shares 292,545,441 291,376,746 291,929,141 290,621,904 Preference shares 3,772,720 3,655,326 3,739,470 3,575,376   Percentages of revenue Cost of revenue 65.1 % 65.2 % 65.5 % 66.1 % Gross profit 34.9 % 34.8 % 34.5 % 33.9 % Selling, general and administrative 17.3 % 19.2 % 17.6 % 18.2 % Gain on sale of dialysis clinics 0.0 % 0.0 % 0.0 % -0.5 % Research and development 0.9 % 0.6 % 0.7 % 0.6 % Operating income (EBIT) 16.6 % 15.0 % 16.3 % 15.5 %   Interest expense, net 3.5 % 4.1 % 3.8 % 4.1 % Earnings before income taxes and minority interest   13.2 % 10.9 % 12.4 % 11.4 % Income tax expense 5.2 % 4.2 % 4.8 % 4.9 % Minority interest 0.2 % 0.3 % 0.3 % 0.2 % Net income 7.7 % 6.5 % 7.4 % 6.3 %   EBITDA   20.7 %   18.8 %       20.0 %   19.1 %     Fresenius Medical CareSegment and Other Information   Three Months EndedDecember 31,       Twelve Months EndedDecember 31,     (in US-$ million)   2007   2006   % Change   2007   2006   % Change   Net revenue North America 1,706 1,658 2.9 % 6,663 6,025 10.6 % International 863 694 24.4 % 3,057 2,474 23.6 % Total net revenue 2,569 2,352 9.2 % 9,720 8,499 14.4 %   Operating income (EBIT) North America 304 260 16.6 % 1,130 965 17.1 % International 159 123 29.0 % 544 440 23.5 % Corporate (35 ) (29 ) 17.0 % (94 ) (87 ) 7.9 % Total operating income (EBIT) 428 354 20.9 % 1,580 1,318 19.9 %   Operating income in percentage of revenue   North America 17.8 % 15.7 % 17.0 % 16.0 % International 18.4 % 17.7 % 17.8 % 17.8 % Total 16.6 % 15.0 % 16.3 % 15.5 %   Excluding one-time items 1) Operating income (EBIT) North America 304 284 6.9 % 1,130 958 18.0 % International 159 123 29.0 % 544 440 23.5 % Corporate (35 ) (28 ) 24.7 % (94 ) (83 ) 12.5 % Total operating income (EBIT) 428 379 12.8 % 1,580 1,315 20.2 %   Operating income in percentage of revenue   North America 17.8 % 17.1 % 17.0 % 15.9 % International 18.4 % 17.7 % 17.8 % 17.8 % Total 16.6 % 16.1 % 16.3 % 15.5 %     Employees Full-time equivalents               61,406     56,803         1) One-time costs associated with restructuring costs, in- process R&D, the transformation of legal form and the gain on FTC mandated sale of clinics in 2006. Fresenius Medical Care             Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measures   Three Months EndedDecember 31,       Twelve Months EndedDecember 31,     (in US-$ million) 2007 2006 % Change 2007 2006 % Change   Operating performance excluding one-time items1) Operating income (EBIT) 428 354 21 % 1,580 1,318 20 % One-time items2) - 25 - (3 ) Operating income (EBIT) excluding one-time items1) 428 379 13 % 1,580 1,315 20 % Percent of revenue 16.6 % 16.1 % 16.3 % 15.5 %   Net income 197 152 30 % 717 537 34 % One-time items2) - 18 - 37 Net income excluding one-time items1) 197 170 16 % 717 574 25 %   Segment information North America Net revenue 1,706 1,658 Costs of revenue and research and development   1,141 1,117 Selling, general and administrative 261 281 Costs of revenue and operating expenses 1,402 1,398 Operating income (EBIT) 304 260 One-time items2) - 24 Operating income (EBIT) excluding one-time items1)   304 284 Percent of revenue 17.8 % 17.1 %   Dialysis Products revenue incl. and excl. internal sales North America Dialysis Products revenue incl. internal sales less 310 284 internal sales (130 ) (131 ) Dialysis Products external sales 180 153 International Dialysis Products revenue incl. internal sales 608 501 less internal sales (75 ) (51 ) Dialysis Products external sales 533 450   Reconciliation of cash flow from operating activities to EBITDA3) Total EBITDA 1,943 1,627 Interest expense, net (371 ) (351 ) Income tax expense (466 ) (413 ) Change in working capital and other non cash items 94 45 Net cash provided by operating activities   1,200 908   Annualized EBITDA4) Operating income (EBIT) last twelve months 1,580 1,367 Depreciation and amortization last twelve months 363 326 Non cash charges 41 35 Annualized EBITDA               1,984     1,728         1) These non US-GAAP financial measures are provided to assist readers in evaluation of Fresenius Medical Care's underlying operating performance. 2) One-time costs associated with restructuring costs, in- process R&D, the transformation of legal form and the gain on FTC mandated sale of clinics as well as the write-off of deferred financing costs related to the 2003 senior credit facility in 2006 as applicable. 3) EBITDA is the basis for determining compliance with certain covenants in Fresenius Medical Care's long-term debt instruments. 4) EBITDA 2006: Pro forma numbers including RCG, before FTC mandated divestitures, excluding one-time costs for the acquisition. Fresenius Medical Care     Balance Sheet   December 31,   December 31, (in US-$ million) 2007 2006   Assets Current assets 3,859 3,412 Intangible assets 7,936 7,554 Other non-current assets 2,375 2,079 Total assets 14,170 13,045   Shareholders' equity and liabilities Current liabilities 3,026 2,376 Long-term liabilities 5,569 5,799 Shareholders' equity 5,575 4,870 Total shareholders' equity and liabilities 14,170 13,045   Equity/assets ratio: 39 % 37 %     Debt Short-term borrowings 217 331 Short-term borrowings from related parties 2 5 Current portion of long-term debt and capital lease obligations 85 160 Current portion of Trust Preferred Securities 670 - Long-term debt and capital lease obligations, less current portion 4,004 3,829 Trust Preferred Securities 664 1,254 Total debt   5,642     5,579   Fresenius Medical Care     Cash Flow Statement   2007   2006 Twelve Months Ended December 31, (in US-$ million)   Operating activities Net income 717 537 Depreciation / amortization 363 309 Change in working capital and other non cash items 120 126 Net tax payments related to clinic divestitures and RCG acquisition - (64 ) Cash Flow from operating activities 1,200 908   Investing activities Purchases of property, plant and equipment (580 ) (467 ) Proceeds from sale of property, plant and equipment 31 17 Capital expenditures, net (549 ) (450 ) Free Cash Flow 651 458   Acquisitions, net of cash acquired (258 ) (4,307 ) Proceeds from divestitures 30 516 Free Cash Flow after investing activities 423 (3,333 )   Financing activities Change in accounts receivable securitization program (181 ) 172 Change in intercompany debt (3 ) (16 ) Change in other debt 19 3,035 Proceeds from exercise of stock options 47 54 Proceeds from conversion of preference shares into ordinary shares - 307 Cash paid for repurchase preferred stock (8 ) - Change in minority interest (27 ) (15 ) Dividends paid (188 ) (154 ) Cash Flow from financing activities (341 ) 3,383   Effects of exchange rates on cash 4 24 Net increase in cash 86 74   Cash at beginning of period 159 85 Cash at end of period   245     159   Fresenius Medical CareReconciliaton of Cash Flow   Three Months EndedDecember 31,   Twelve Months EndedDecember 31, (in US-$ million)   2007   2006   2007   2006   Net cash provided by operating activities adjusted 309 443 1,200 1,106 Tax payments for prior years - - - (99 ) RCG acquisition - - - (99 ) Net cash provided by operating activities 309 443 1,200 908   Capital expenditures (net) (184 ) (177 ) (549 ) (450 )   Free Cash Flow adjusted 125 266 651 656 Tax payments for prior years - - - (99 ) RCG acquisition - - - (99 ) Free Cash Flow 125 266 651 458   Divestitures adjusted - - 30 - RCG acquisition - 9 - 516 Divestitures - 9 30 516   Acquisitions adjusted (118 ) (115 ) (258 ) (159 ) RCG acquisition - (3 ) - (4,148 ) Acquisitions (118 ) (118 ) (258 ) (4,307 )   Free Cash Flow after acquisitions and divestitures adjusted 7 151 423 497 Tax payments for prior years - - - (99 ) RCG acquisition - 6 - (3,731 ) Free Cash Flow after acquisitions and divestitures   7     157     423     (3,333 ) Fresenius Medical Care         Quarterly Performance Scorecard - Revenue                 Three months ended December 31, 2007 cc 2006 cc (in US-$ thousands, except per-treatment revenue)   North America Net revenue 1,705,741 1,658,076 Growth year-over-year 2.9 % 38.9 %   Dialysis Care 1,525,799 1,504,896 Growth year-over-year 1.4 % 43.5 % U.S. per treatment 325 328 Per treatment 321 325 Sequential growth -0.6 % 1.2 % Growth year-over-year -1.3 % 8.7 %   Dialysis Products incl. internal sales 310,017 283,866 Growth year-over-year 9.2 % 19.6 % External sales 179,942 153,180 Growth year-over-year 17.5 % 5.3 %   International Net revenue 863,483 694,274 Growth year-over-year 24.4 % 12.3 % 20.1 % 14.0 %   Dialysis Care 330,532 244,430 Growth year-over-year 35.2 % 22.2 % 17.5 % 12.6 % Per treatment 160 145 138 133 Sequential growth 4.4 % 4.7 % Growth year-over-year 15.5 % 4.4 % 8.8 % 4.3 %   Dialysis Products incl. internal sales 607,807 501,055 Growth year-over-year 21.3 % 9.3 % 18.9 % 12.4 % External sales 532,951 449,844 Growth year-over-year   18.5 %   7.0 %   21.5 %   14.8 %   cc = at constant exchange rates Fresenius Medical Care     Quarterly Performance Scorecard - Dialysis Care Volume         Three months ended December 31, 2007 2006   North America Number of treatments 4,752,697 4,540,797 Treatments per day 59,409 57,475 Per day sequential growth 0.3 % 0.9 % Per day year-over-year growth 3.4 % 32.2 % of which: - Acquisition RCG 0.0 % 32.9 % - FTC divestitures 0.0 % -3.2 % - Other acquisitions 0.6 % 0.5 % - Same market growth year-over-year 3.0 % 2.3 % - Adjustments for closed/sold facilities, yield and other -0.2 % -0.3 %   International Number of treatments 2,066,472 1,765,471 Same market growth year-over-year   6.2 %   9.1 %     Fresenius Medical Care Quarterly Performance Scorecard - Expenses         Three months ended December 31, 2007 2006   North America Costs of revenue and operating expenses Percent of revenue1) 82.2 % 84.3 % Selling, general and administrative Percent of revenue1) 15.3 % 17.0 % Bad debt expenses Percent of revenue 2.7 % 2.9 % Dialysis Care operating expenses/Treatment (in US-$) 263 267 Sequential growth -2.0 % -0.5 % Growth year-over-year -1.7 % 4.4 %   Total Group Costs of revenue and operating expenses Percent of revenue2) 83.4 % 85.0 % Selling, general and administrative Percent of revenue2) 17.3 % 19.2 % Effective tax rate   39.8 %   38.5 %   1) 2006 includes 1.4% restructuring costs and in-process R&D. 2) 2006 includes 1.1% restructuring costs, in-process R&D and costs for the transformation of legal form. Fresenius Medical Care     Quarterly Performance Scorecard - Cash Flow/Investing Activities         Three months ended December 31, 2007 2006 (in US-$ thousands, except number of de novos)   Total Group Operating Cash Flow 309,371 442,839 Percent of revenue 12.0 % 18.8 %   Free Cash Flow before acquisitions 124,846 265,606 Percent of revenue 4.9 % 11.3 %   Acquisitions, net 118,285 117,745   Divestitures - (9,012 )   Capital expenditures, net 184,525 177,234 Percent of revenue 7.2 % 7.5 %   Maintenance 87,327 75,640 Percent of revenue 3.4 % 3.2 %   Growth 97,198 101,594 Percent of revenue 3.8 % 4.3 %   Number of de novos 17 26 North America 10 18 International   7     8       Fresenius Medical Care Quarterly Performance Scorecard - Balance Sheet         Three months ended December 31, 2007 2006   Total Group Debt (in US-$ million) 5,642 5,579 Debt/EBITDA 2.8 3.2   North America Days sales outstanding 58 59 Sequential development 1.8 % 1.7 % Year-over-year development -1.7 % -6.3 %   International Days sales outstanding 110 119 Sequential development -3.5 % -2.5 % Year-over-year development   -7.6 %   -0.8 % Fresenius Medical Care     Quarterly Performance Scorecard         Three months ended September 30, 2007 20061)   Clinical Performance North America (U.S.) Single Pool Kt/v > 1.2 95 % 95 % Hemoglobin >= 11g/dl 80 % 83 % Albumin >= 3.5 g/dl 2) 80 % 80 % Hospitalization days per patient 3) (12 months ending Dec 31,) 9.9 10.1     Demographics North America (U.S.) Average age (yr) 62 62 Average time on dialysis (yr) 3.5 3.5 Average body weight (kg) 79 78 Prevalence of diabetes   53 %   52 %   1) Q4 2006 data: without former RCG facilities 2) International standard BCR CRM470 3) Hospitalization data without former RCG facilities